Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. By admin / 12/04/2016
Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies By admin / 10/27/2016
Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas. By admin / 12/08/2015
Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma. By admin / 12/09/2014
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells. By admin / 12/10/2013
